KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company that developed and commercialized EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema attacks, serving HAE patients aged 12 and older across the US, Europe, and Japan.
- Company typePublic
- Founded2012
- HeadquartersCambridge, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What KalVista Pharmaceuticals does
KalVista Pharmaceuticals is a clinical and commercial-stage biopharmaceutical company that develops orally delivered small molecule protease inhibitors for rare diseases, with a primary focus on hereditary angioedema (HAE). The company's lead asset, EKTERLY (sebetralstat), is a plasma kallikrein inhibitor that blocks the kallikrein-kinin system (KKS) pathway mediating acute HAE attacks; it is the first and only oral on-demand treatment approved for HAE, holding regulatory clearances in the United States, United Kingdom, European Union, Japan, Australia, Switzerland, and Singapore following FDA approval on July 7, 2025. KalVista generates revenue from global net product sales of EKTERLY, distributed in the US through specialty pharmacy partner Orsini and internationally through regional commercialization partners (Kaken in Japan, Pendopharm in Canada, Multicare in Latin America), reaching 1,702 patient starts and 724 prescribing physicians representing approximately 20% of the US HAE patient population within roughly six months of launch. The company also runs the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2-11 and maintains a preclinical oral Factor XIIa inhibitor program targeting HAE prophylaxis. KalVista was acquired by Italy-based Chiesi Group for $1.9 billion in June 2026 and now operates as a wholly owned subsidiary.
KalVista Pharmaceuticals firmographics
Firmographics- Name
- KalVista Pharmaceuticals
- Legal name
- KalVista Pharmaceuticals
- Website
- https://kalvista.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 251–500 employees
- Short description
- KalVista Pharmaceuticals is a biopharmaceutical company that developed and commercialized EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema attacks, serving HAE patients aged 12 and older across the US, Europe, and Japan.
- Ownership category
- akta.pro rank
KalVista Pharmaceuticals industry classification
Industry- Product category
- Hereditary Angioedema Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
- akta.pro secondary industry
- Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)
Keywords
Where KalVista Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
KalVista Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- EKTERLY Product Sales: Global net product revenue from commercial sales of EKTERLY (sebetralstat) following regulatory approvals. Generated $49.1 million in global net product revenue for the eight months ended December 31, 2025, driven by US commercial launch on July 7, 2025, with international expansion to Germany and Japan.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription pharmaceutical product for HAE patients |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels5 records
KalVista Pharmaceuticals product offering
Product offeringCore offering
KalVista Pharmaceuticals develops, manufactures, and commercializes oral small molecule protease inhibitor therapies, beginning with EKTERLY (sebetralstat) - the first and only oral, on-demand treatment for acute hereditary angioedema attacks in patients aged 12 and older. The company is also advancing a preclinical oral Factor XIIa inhibitor program for HAE prophylaxis and a pediatric clinical program (KONFIDENT-KID) for children aged 2-11, distributing globally through specialty pharmacy and regional pharmaceutical partners.
Product overview
KalVista Pharmaceuticals is a global biopharmaceutical company developing and delivering oral therapies for rare diseases, beginning with hereditary angioedema (HAE). The company's commercial product is EKTERLY (sebetralstat), the first and only oral on-demand treatment for HAE attacks, approved in the US (July 2025), UK, EU, Japan, and other markets. The pipeline includes an oral Factor XIIa inhibitor in preclinical development for HAE prophylaxis and other conditions. The company was acquired by Chiesi Group in June 2026 and operates as a wholly owned subsidiary.
Differentiator
Problem solved
Functional benefit
Brands
- EKTERLY (sebetralstat): First and only oral on-demand treatment for hereditary angioedema (HAE) attacks, approved in the US, UK, EU, Japan, and other markets
- KalVista Cares
- KONFIDENT-KID
Products and services
- EKTERLY (sebetralstat) First and only oral, on-demand plasma kallikrein inhibitor approved for the treatment of acute hereditary angioedema attacks in patients aged 12 and older. It provides a non-invasive alternative to injectable therapies, enabling patients to treat attacks without needles.
- KONFIDENT-KID (pediatric sebetralstat clinical program) Open-label Phase 3 clinical program evaluating sebetralstat in a proprietary oral disintegrating tablet formulation for on-demand treatment of hereditary angioedema attacks in pediatric patients aged 2-11.
- Oral Factor XIIa Inhibitor Program Preclinical oral Factor XIIa inhibitor program being studied as a treatment for HAE prophylaxis, expanding the HAE portfolio to include prophylactic treatment, and exploring potential applications in inflammation and thrombosis.
- KalVista Cares Comprehensive patient support program offering personalized services for eligible patients prescribed EKTERLY, including help navigating insurance coverage, access support, and financial assistance.
Quantifiable outcome
- 93.7% of caregivers experienced anxiety about injectable treatments; 47% of pediatric patients required emergency room care
- +4 more outcomes
Companies that use KalVista Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
KalVista Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
KalVista Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered flagship and core.
- Chiesi GroupflagshipChiesi Group completed acquisition of KalVista Pharmaceuticals on June 11, 2026 for $1.9 billion ($27 per share), making KalVista a wholly owned subsidiary. The acquisition brings EKTERLY (sebetralstat) into Chiesi's rare disease portfolio, with regulatory approvals across US, UK, EU, Japan, and other markets.
- Multicare PharmaceuticalscorePartnership to commercialize EKTERLY (sebetralstat) in Brazil, Argentina, Colombia, and Mexico. This marks KalVista's third commercial partnership in ten months, expanding access to the first oral on-demand HAE treatment across Latin America.
- Kaken PharmaceuticalcoreJapan-based partner responsible for commercialization of EKTERLY in Japan following Ministry of Health, Labor and Welfare approval. The medication was listed on Japan's National Health Insurance drug reimbursement system.
- OrsinicoreSpecialty pharmacy partner for EKTERLY in the United States, providing specialized distribution and patient support services for the rare disease medication.
- Pendopharm (Pharmascience Inc.)coreExclusive distribution agreement for sebetralstat in Canada, with Pendopharm managing regulatory approval and commercialization as the first oral on-demand HAE treatment in Canada.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
KalVista Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- BioCryst Pharmaceuticals: Direct HAE competitor marketing Orladeyo (berotralstat), the first oral prophylactic HAE therapy. BioCryst and KalVista are the two pure-play oral HAE innovators competing in the same rare disease market with complementary on-demand vs. prophylaxis positioning.
Emerging players
- Pharvaris: Clinical-stage company developing oral bradykinin B2 receptor antagonists (PHVS416, PHVS719) for both HAE on-demand treatment and prophylaxis. Pharvaris is the most direct emerging competitor to EKTERLY with an overlapping oral HAE strategy.
- Ionis Pharmaceuticals: Antisense oligonucleotide platform company developing therapies for rare diseases, including a Factor XI antisense program relevant to the thrombosis space that KalVista's Factor XIIa program also targets. Comparable as a small-cap rare disease innovator.
Broad incumbents
- Takeda Pharmaceutical: Acquired Shire's HAE franchise including Takhzyro (lanadelumab) for HAE prophylaxis and Firazyr (icatibant) for on-demand treatment. Takeda is the dominant incumbent in HAE with multiple established therapies competing directly with EKTERLY's on-demand positioning.
- Swedish Orphan Biovitrum (Sobi): Rare disease specialist that markets Cinryze (C1-inhibitor replacement) for HAE prophylaxis outside the US. Sobi's established HAE franchise and rare disease commercial infrastructure make it a relevant peer in the broader rare disease therapeutics space.
- CSL Behring: Plasma-derived therapy leader marketing Berinert (C1-esterase inhibitor) and Haegarda for HAE treatment. CSL Behring's established plasma fractionation infrastructure and HAE franchise position it as a key incumbent competing with oral therapies like EKTERLY.
- Recordati: European specialty pharmaceutical company with a rare disease franchise including HAE treatments (Ruconest via Pharming partnership). Recordati's rare disease commercial infrastructure and European market presence are comparable to Chiesi's positioning relative to KalVista.
- Alexion / AstraZeneca Rare Disease: AstraZeneca's rare disease unit following acquisition of Alexion, with a leading franchise in complement-mediated diseases. The complement/kallikrein-kinin system overlap with HAE biology makes Alexion thematically relevant to KalVista's therapeutic approach.
- Vertex Pharmaceuticals: Commercial-stage rare disease leader (cystic fibrosis, sickle cell) that recently expanded into broader rare disease therapeutics. Vertex's track record of taking oral small molecules from rare disease R&D through global commercialization is comparable to the trajectory KalVista has followed.
- Chiesi Group: Italy-based global pharmaceutical company focused on rare diseases that acquired KalVista for $1.9B in June 2026. Chiesi's rare disease portfolio and global commercialization capabilities now absorb KalVista's assets, making it the parent context for forward evaluation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
KalVista Pharmaceuticals social profiles
Digital presenceKalVista Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
KalVista Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles11 records
KalVista Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds8 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KalVista Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KalVista Pharmaceuticals
What does KalVista Pharmaceuticals do?
KalVista Pharmaceuticals develops, manufactures, and commercializes oral small molecule protease inhibitor therapies, beginning with EKTERLY (sebetralstat) - the first and only oral, on-demand treatment for acute hereditary angioedema attacks in patients aged 12 and older. The company is also advancing a preclinical oral Factor XIIa inhibitor program for HAE prophylaxis and a pediatric clinical program (KONFIDENT-KID) for children aged 2-11, distributing globally through specialty pharmacy and regional pharmaceutical partners.
Is KalVista Pharmaceuticals a public or private company?
KalVista Pharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.
When was KalVista Pharmaceuticals founded?
KalVista Pharmaceuticals was founded in 2012. It employs 251 to 500 people.
Where is KalVista Pharmaceuticals based?
KalVista Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
How does KalVista Pharmaceuticals make money?
One revenue line is on record: EKTERLY Product Sales.
Who are KalVista Pharmaceuticals's main competitors?
BioCryst Pharmaceuticals is listed as a direct peer. Emerging players are Pharvaris and Ionis Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical, Swedish Orphan Biovitrum (Sobi), CSL Behring, Recordati, Alexion / AstraZeneca Rare Disease, Vertex Pharmaceuticals and Chiesi Group.
Does KalVista Pharmaceuticals have an API?
No public API is recorded for KalVista Pharmaceuticals.
What industry is KalVista Pharmaceuticals in?
KalVista Pharmaceuticals's product category is Hereditary Angioedema Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.